PPARA and Abnormal renal physiology: Elevated plasma pemafibrate concentrations have not been noted in single-dose or repeated-dose studies of patients with renal dysfunction [14,15], or in drug-drug interaction studies of pemafibrate with various statins [16], suggesting that pemafibrate may represent a new drug category distinct from the conventional PPARα agonists.